Contrasting of Sangamo Therapeutics Inc. (SGMO) and MediciNova Inc. (NASDAQ:MNOV)

We are contrasting Sangamo Therapeutics Inc. (NASDAQ:SGMO) and MediciNova Inc. (NASDAQ:MNOV) on their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sangamo Therapeutics Inc. 70.69M 12.02 62.76M -0.69 0.00
MediciNova Inc. N/A 0.00 16.07M -0.42 0.00

Table 1 highlights Sangamo Therapeutics Inc. and MediciNova Inc.’s top-line revenue, earnings per share and valuation.


Table 2 provides the net margins, return on equity and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
Sangamo Therapeutics Inc. -88.78% -22.1% -13.9%
MediciNova Inc. 0.00% -24.4% -23.1%

Volatility and Risk

Sangamo Therapeutics Inc. has a beta of 3.04 and its 204.00% more volatile than S&P 500. In other hand, MediciNova Inc. has beta of 0.86 which is 14.00% less volatile than S&P 500.


6.3 and 6.3 are the respective Current Ratio and a Quick Ratio of Sangamo Therapeutics Inc. Its rival MediciNova Inc.’s Current and Quick Ratios are 34.8 and 34.8 respectively. MediciNova Inc. has a better chance of clearing its pay short and long-term debts than Sangamo Therapeutics Inc.

Analyst Ratings

Sangamo Therapeutics Inc. and MediciNova Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Sangamo Therapeutics Inc. 0 2 0 2.00
MediciNova Inc. 0 0 0 0.00

The upside potential is 32.21% for Sangamo Therapeutics Inc. with average price target of $11.

Institutional and Insider Ownership

The shares of both Sangamo Therapeutics Inc. and MediciNova Inc. are owned by institutional investors at 66.2% and 24.5% respectively. Insiders owned roughly 0.1% of Sangamo Therapeutics Inc.’s shares. Competitively, insiders own roughly 11.44% of MediciNova Inc.’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Sangamo Therapeutics Inc. -5.58% -18.32% -20.27% -25.37% -32.09% -28.78%
MediciNova Inc. -11.35% -27.38% -24.4% -4.33% 28.16% 36.48%

For the past year Sangamo Therapeutics Inc. has -28.78% weaker performance while MediciNova Inc. has 36.48% stronger performance.

Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The companyÂ’s proprietary zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and Phase I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for hemophilia B, Hemophilia A, and Mucopolysaccharidosis I (MPS) and MPS II, which are lysosomal storage disorder (LSD); proprietary preclinical programs in other LSDs; and research stage programs in certain central nervous system disorders and cancer immunotherapies. It has collaborative partnerships with Biogen Inc. to develop therapeutic genome editing products in hemoglobinopathies; and with Shire International GmbH to develop the preclinical development program in HuntingtonÂ’s disease, as well as license agreement with Sigma-Aldrich Corporation to develop ZFP-based laboratory research reagents and Dow AgroSciences, LLC to modify the genomes or alter protein expression of plant cells, plants, or plant cell cultures. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.

MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company’s product candidate includes MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders, including primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction, including methamphetamine, opioid, and alcohol dependence. Its product pipeline also comprises MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, such as nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, and other fibrotic diseases; MN-221 (bedoradrine), a ß2-adrenergic receptor agonist for the treatment of acute exacerbation of asthma; and MN-029 (denibulin), a tubulin binding agent to treat solid tumor cancers. The company was founded in 2000 and is headquartered in La Jolla, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.